2023-506396-94-00已完成1 期
A first-in-human phase 1, single center, randomized, double-blind, placebo-controlled study to evaluate the safety and immunogenicity of three dose levels of the OVX033 vaccine, after intramuscular administration in healthy subjects aged 18-49 years
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 发起方
- Osivax
- 入组人数
- 48
- 试验地点
- 1
研究概览
简要总结
暂无简介。
入排标准
- 年龄范围
- 18 years 至 64 years（18-64 Years）
- 接受健康志愿者
- 是
入选标准
- 未提供
排除标准
- 未提供
研究者
Florence Nicolas - Chief Development Officer
Scientific
Osivax
研究点 (1)
Loading locations...
相似试验
已完成
1 期
A randomized first-in-human, Phase 1, single-center, observer-blind, active-controlled 3-arm study to evaluate the safety, tolerability, and immunogenicity of one single administration of TETRALITE, a novel adjuvanted influenza vaccine, in healthy participants aged 18 to 50 yearsInfluenza2022-500681-98-00Litevax B.V.60
尚未招募
不适用
A phase 1 clinical trial to evaluate safety, tolerability, pharmacokinetic properties and effectiveness after applying an investigational cream to healthy adults and atopic dermatitis patientsDiseases of the skin and subcutaneous tissueKCT0005182Avixgen24
招募中
不适用
A Randomized, Observer-blind, First-in-Human Phase 1/2a Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Three Different Doses of VAC52416 (ExPEC10V) in Adults Aged 60 to 85 Years in Stable HealthNL-OMON52538Janssen-Cilag80
进行中（未招募）
1 期
A Study of Three Different Doses of VAC52416 (ExPEC10V) in Adults Aged 60 to 85 Years in Stable HealthHealthy volunteers (Prevention of invasive extraintestinal pathogenic Escherichia coli (ExPEC) disease)EUCTR2020-000657-27-FRJanssen Vaccines & Prevention B.V.1,004
进行中（未招募）
1 期
A Study of Three Different Doses of VAC52416 (ExPEC10V) in Adults Aged 60 to 85 Years in Stable HealthEUCTR2020-000657-27-NLJanssen Vaccines & Prevention B.V.1,004